Induced Pluripotent Stem Cell (iPS Cells) - Content Archive

Mytos Advances Automated iPSC Manufacturing through Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip

September 29, 2025 By BioInformant Team Leave a Comment

Mytos Announces Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip to Power Next-Generation Cell Therapy Trials

Mytos’ iDEM platform replaces traditional iPSC manufacturing with a closed, automated system that delivers consistent, GMP-ready cells while reducing cost, variability, and time to clinic

Collaborations highlight the versatility of Mytos’ iDEM platform across diverse cell types and clinical applications from blindness and hearing loss to complex bone regeneration

Ncardia Launches First-of-Its-Kind iPSC-Derived Non-Human Primate Cardiomyocytes to Advance Cardiac Safety Research

September 26, 2025 By BioInformant Team Leave a Comment

LEIDEN, Netherlands — Ncardia, a leader in stem cell–based solutions for drug discovery and safety assessment, today announced the launch of Ncyte^® NHP-C vCardiomyocytes, the first commercially available ventricular-like cardiomyocytes derived from induced pluripotent stem cells (iPSCs) of cynomolgus monkeys. New Ncyte® NHP-C vCardiomyocytes provide a scalable, ethical and translational tool for cross-species cardiac studies. [Read more…]

Interview With Kaz Hirao, President & COO at Fujifilm Cellular Dynamics

September 19, 2025 By Cade Hildreth, Founder & President Leave a Comment

Fujifilm CDI is the largest provider of induced pluripotent stem cell (“iPSC” or “iPS cell”) products worldwide. In addition to being a global leader for life science products, CDI divided into two business units (Life Science and Therapeutics), positioning it to further invest in the development of iPSC-derived cell therapeutics.

The company also opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.

[Read more…]

Historic Patent Challenges to Pluripotent Stem Cells (ESCs and iPSCs)

September 18, 2025 By BioInformant Team 1 Comment

The patent landscape for pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), is characterized by groundbreaking discoveries, legal challenges, and debates over accessibility. The patent environment surrounding these stem cell types is complicated, and there are a number of restrictions on how the cells can be used for commercial and strategic purposes. [Read more…]

Cartherics Wins ‘Most Promising iPSC Therapy Pipeline in APAC’ at Asia Pacific Cell & Gene Therapy Excellence Awards

September 12, 2025 By BioInformant Team Leave a Comment

Melbourne, Australia, 11 September 2025 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, is proud to announce that it has been named ‘Most Promising iPSC Therapy Pipeline in APAC’ in the Asia Pacific Cell & Gene Therapy Excellence Awards 2025 (APCGTEA 2025). [Read more…]